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1. Introduction
More than 80, 000 of the 250, 000 species of flowering plants have been reported to be used by
human civilizations for medicinal purposes [1]. This figure could be higher as information on
the native uses of plants as medicines was mainly passed on verbally from one generation to
another and has mostly stayed unregistered. Some of the traditional knowledge might be lost
as some practitioners were secretive and reluctant to reveal enough information. Information
on the ancient uses of plant materials as medicines can be found in archeological finds,
archives, ancient documents, history books and pharmacopoeias. Fossil records date human
use of plants as medicines at least to the Middle Paleolithic age some 60, 000 years ago [2]. The
World Health Organization (WHO) estimated that as much as 80 per cent of the world’s
population relies on traditional forms of medicine, chiefly plants [3]. The tropical rainforest
plants are biologically and chemically diverse resource as they synthesize a wide spectrum of
organic molecules as defense agents against diseases, pests and predators. They have been
shown to be the source of chemicals of diverse structures with promising biological activities
and perhaps the most valuable source of therapeutic agents due to their rich biodiversity [4].
Tropical rainforests have been called the ‘world's largest pharmacy’, because over one quarter
of natural medicines have been discovered within them; additionally, about 70% of the drugs
used today are models of natural products. Plants have always been a rich source of natural
products and historically provided many major new drugs. Natural products or natural
product-derived compounds signify great structural variety, which is not usually found in
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synthetic compounds. Of the 1184 new chemical entities reported through 1981 to 2006, 60%
were derived from or based on natural products. Twenty-five percent of all prescription
medications are made using the various types of secondary metabolites from living organisms,
mainly plants [5-9].
One hundred twenty-one prescription drugs are made from higher plants. This does not
include antibiotics from microorganisms. Among the world’s 25 best-selling pharmaceutical
agents, 12 are natural product-derived [10], and natural products are playing key role in drug
discovery programs of the pharmaceutical industry and various research organizations
[11-13]. Half of these plant-based medicines come from the tropics, and 74% of these came from
native folklore. Seventy percent of the plants identified as having anti-cancer characteristics
by the US National Cancer Institute are found only in the tropical rainforests. Quinine, the first
known antimalarial, comes from a neotropical tree, and curare, used as a poison for arrow tips
by indigenous peoples in the Neotropics, is also useful for heart conditions. As new medical
discoveries are being made all the time obviously, the tropical rainforests and their resources
such as natural products find place in every part of our life. Plants have evolved and adapted
over millions of years to withstand bacteria, insects, fungi and weather to produce unique,
structurally diverse secondary metabolites.Therefore, natural products play a leading role in
the research of leads for the development of drugs for treating human diseases [14]. The
investigation of biological and chemical properties of natural products for the past two
centuries has not only produced drugs for the treatment of several diseases, but has instigated
the development of synthetic organic chemistry, and the arrival of medicinal chemistry as a
major route to discover efficacious and novel therapeutic agents. Structural alteration of
natural compounds or synthesis of novel compounds, based on designs following a natural
compound scaffolding, have offered us a lot of vital new drugs in the fields of medicine,
agriculture, and food spheres [15-16].
2. History of drug discovery and development
Medicinal plants have been used by mankind since ancient times as the main source of
medicines. Originally the choice of plants to treat various ailments was on an irrational basis
as it was strongly influenced by ideologies of the primitive societies which were deeply rooted
in mysticism and superstition. They believed, for example, a person became ill because evil
spirits dwelled in his body. Plants with unpleasant odor and taste, accompanied by enchant‐
ments and ceremonial dances, were used to get rid of the demons and the person would then
recover from his illness. However, the selection of plants for medicinal purposes became more
rational when it was influenced and shaped by new philosophies and religions [17]. In the
search for remedies from plants many different theories of disease were proposed and the
choice of plants was based on these ideas. Although the ancient peoples were ignorance on
the etiology of disease and the mechanism by which the medicinal agents made the disease
disappear, they tried to establish a relationship between them. One of the earliest theory was
the concept of plant signature which claimed that God provided visual sign (signature) in
plants that permits us to recognize and utilize them to cure diseases [18]. Signature plants were
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probably first recognized in ancient China, where there was classification that associated plant
features to human organs. ‘Yang’ was linked to strong acting plants: diseases of upper half of
the body were treated with upper parts of plants, whereas ‘Yin’ was related with plants
possessing modest action and those with sweet, salty, sour and bitter tastes; underground parts
of the plant were used to treat the diseases of lower parts of the body [19]. Signature plants
emerged for medicinal uses in western cultures during the Middle Ages. Paracelsus Doctrine
of Signature, published in the 16th century, was a theory based on signature plants [17].
The signature plants provided a way of reducing the complexity of selecting plants to treat
diseases. However, the traditional medicine practitioners of many cultures did not depend on
the Doctrine of Signatures alone for knowledge of the proper use of a medicinal plant. A wide
range of plants were experimented by trial and error to treat diseases and discovered that
certain plants were effective against a number of diseases. The ‘crude clinical trials’ were
actually a screening process but they could also possibly have produced many adverse effects,
casualties and possibly thousands of deaths resulted from the toxicity of some of the plants.
Several thousands of plants had been screened and based on their long-term use by human,
one might expect that plants presently in use in traditional medicine produced some beneficial
effects and have low human toxicity. If a plant showed acute toxic effects following its use to
treat illness it would then not be used at all. However, if a plant had chronic toxic effects it
would be less likely be noticed and it would continue to be used [20]. Moreover, there was lack
of reporting system to document these effects as most information was passed on only by word
of mouth. The information derived from the empirical knowledge and theories on the use of
plants, although has been regarded with interested skepticism, had contributed towards the
early development of medicinal agents from plants. The traditional knowledge and practices
on the use of medicinal plants for treating diseases rely exclusively on practical experience and
observation passed on verbally from one generation to the next with little documentation. It
is necessary to understand the contemporary relevance of empirical knowledge and the
interpretation of this knowledge using modern methods in the chemical and biological studies
of substances [20].
During the course of history, natural products have offered a variety of compounds that have
extensive applications in the fields of medicine, food and agriculture [21]. Higher plants in
particular have been the basis of medicinal agents for centuries, and presently they play key
roles in the primary health care of 80% of the world [22]. Medicinal agents and natural products
therefore, are also a significant feature in the health care systems of the residual 20% of the
population living in developed countries, with more than half of all the drugs in clinical use
having sourced from natural products [23].The earliest history of the identification of novel
bioactive compounds from natural sources can be traced back in 1804 when a young German
pharmacist had successfully isolated morphine from the seed pods of the poppy, Papaver
somniferum [24]. Since then, it marked the birth of the study on purification and the effects of
drugs from natural products. This classical example represents most of the drug discovery
process from natural products, where majority of new drugs have been discovered by direct
isolation from natural sources and molecular modification of natural products. The phenotypic
screening and single target or bullet-based approach have been the dominant paradigms to
The Evolving Role of Natural Products From the Tropical Rainforests as a Replenishable Source of New Drug Leads
http://dx.doi.org/10.5772/59603
5
discover natural small organic molecules from natural resources as new leads or models for
the development of synthetic molecules for the discovery of drug targets.
Plant-based traditional medicine systems have been in existence for centuries in countries like
China [25], India [26], the Malay Archipelago, and medicinal plants are used widely in African
traditional health systems [27-28]. Many phytomedicines are registered and extensively used
in Europe, and more than 600 botanical items have been legitimately documented in various
editions of the United States Pharmacopoeia[29], however existing rules forbid most from
being marketed as drugs. According to the WHO, majority of population still rely on plant-
based traditional medicines for primary health care [30] and 80% of 122 plant derived drugs
were related to their original ethnopharmacological purposes [31]. The knowledge associated
with traditional medicines has promoted further investigations of medicinal plants as potential
medicines and has led to the isolation of many natural products that have become well known
pharmaceuticals. Until the 1950s almost all drug research relied heavily on vascular plants as
sources of medicines. Plant-based traditional knowledge has become a recognized tool in
search for new sources of drugs [32]. Most of the early discoveries of plant-derived drugs were
by examining the use of these plants in traditional medicine. The phytochemicals isolated
directly from plants were used unmodified as drugs. Morphine, isolated from opium poppy
(Papaver somniferum) was the first plant-derived drug. Other examples include reserpine, an
antihypertensive drug, from the root of Rauvolfia serpentina. the cardiac glycosides digoxin and
digitoxin from Digitalis lanata, and the anticancer agents, vincristine and vinblastine from
Catharanthus roseus [33]. The anticancer area, in particular, has made great use of natural
products such as vinblastine and vincristine (vinca alkaloids), etoposide and teniposide
(podophylltoxin analogues), paclitaxel (taxol), and camptothecin–derived topotecan. In the
past ten years, 62% of the new anticancer-agents have been natural products or based on
natural products models [31].
3. Conventional approach of drug discovery from natural products
History had shown that serendipity played a major role in the finding of novel drugs. One
classical example that warrant a repetition was the discovery of penicillin, an antibiotic
produced by Penicillium notatum, by Alexander Fleming in 1928. Henry Harris once said that
‘Without Fleming, no Chain; without Chain, no Florey; without Florey, no Heatley; without
Heatley, no penicillin.’ After several years, the main active component was finally determined
to be benzylpencillin which lysis the staphylococcal colonies on an agar plate [34]. The impact
of the aforementioned example was so great that more scientists at that time started to look
into natural products as the main source of leads. Since then, more structured strategies in
natural products drug discovery were implemented in choosing plants for biological screening
such as the ethnobotanical approach, chemotaxonomic approach or the phylogenetic survey
screening, phenotypic screening and the single target or bullet-based approach.
The selection of plants based on traditional knowledge serves as the initial biological screening
in a drug discovery program. The selection of plant samples for biological screening is
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generally based on the indigenous uses of plants. The ethnobotanical approach is more
targeted and the most successful of the plant-surveying methods. The indigenous uses of
plants offer important clues or information on the biological activities of those plants which
are based on accumulated past knowledge and experiments by ancient civilization. Undenia‐
bly, some of the effectiveness of these plant extracts have been refuted due to the placebo effect
in the patients, it is still one of the best approach for identifying leads. For example, plants
used traditionally against diseases possibly caused by viruses are collected for anti-HIV
screening [33]. The ethnobotanical field searches have generated many lead compounds which
have been identified as drug candidates for the development of many therapeutic agents such
as antiviral, antifungal and anticancer drugs. There are many important discoveries that lead
to the development of more effective and safer drugs. Prostratin, a powerful antiviral agent,
was found in the aqueous extract of Homalanthus nutans which is used in Samoa to treat yellow
fever. A novel compound that kills parasitic worms in the stomach was isolated form Curcuma
comosa which is used in Thailand to ease stomach pains and other gastrointestinal disorders.
The extracts of ipecacuanha root, found in the genus of the Rubiaceae family, was used in the
Aztec and Mayan cultures to treat amoebiasis and emetine, the bioactive compound respon‐
sible for the activity had been isolated from the plant [35]. Due to the adverse side-effects, a
synthetic compound dehydroemetine was synthesized. Codeine which is found in the opium
poppy, Papaver somniferum, is widely used for the treatment of moderate pain. The use of
codeine can be traced back hundreds of years far back in the Egyptians and the Ancient Chinese
history. Another plant extract known as ma huang or ‘Yellow Hemp’ has been used by the
Chinese to treat asthma and hay fever for thousands of years [36]. It was not until 1926, when
the active ingredient, ephedrine was introduced into the Western medicine as an orally active
bronchodilator to treat acute asthma. Another important example is the use of cinchona bark
from the species Cinchona succirubra by the Quechua, South American Indians in the treatment
of fevers. The active ingredient, quinine was the first effective treatment for malaria caused by
Plasmodium falciparum. Other plant that possess antimalarial activity was reported by the
Chinese herbalist known as Artemisia annua or sweet wormwood which had been described
in a 4th century text. Studies have shown that the active compound responsible for the
antimalarial properties was artemisinin [33, 37].
Phylogenetic survey or chemotaxonomic method is a plant-collecting method where research‐
ers select relatives of plants identified to yield useful compounds. The ecological survey is a
selection made on the basis of defensive features of the plants against predators, indicating
that they produce chemicals capable to exert an effect on animals. The non-targeted method
(haphazard collection of plant samples) is practiced by researchers particularly in areas
involving biological diversity, nonetheless the success rate is poor [33]. Taxol, derived from
Taxus brevifolia, is a notable example of anticancer drug discovered by a random screening
program. In phenotypic screening, pure compounds or extracts from plants are screened
through in vitro followed by in vivo or vice versa to monitor the desirable change in phenotype
before an effort is made to determine the biological target. Meanwhile the single target
approach requires a molecular structure (active site or receptor) that will undergo a specific
interaction with the so called plant extracts or pure compounds when they are administered
to treat a certain disease. While these two pharmacological approaches are still commonly
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practiced in most of the universities and research centers in developing countries, the chances
of finding bioactive compounds from plants are highly serendipitous. To minimize the time
consumption and tedious laboratory work, a directed screening is principally carried out on
medical folkloric plants.
Methods adopted in the natural products isolation or bioassays screening have been rather
straightforward. Crude extracts obtained from the dried or fresh plants are extracted with
aqueous or organic solvents such as water, methanol, chloroform, hexane, and ethyl acetate.
The practical of this isolation method can be found since the Mesopotamian and Egyptian
civilizations where natural products extraction had been a common practice to produce
perfumes or pharmaceutical products. Simple soxhlet extraction, maceration, hydro-distilla‐
tion, and other solvent extractor techniques have been employed in the past and present, albeit
large quantity of plant samples are generally required to obtain pure compounds. Conven‐
tional chromatography methods such as column and planar chromatography which rely on
the differential partitioning between the mobile and stationary phases play important roles in
drug discovery from natural products. Before new chromatographic methods were developed,
isolation of minor compounds from plant extracts was relatively difficult. In recent time, the
weaknesses using these conventional methods have been gradually solved by the replacement
with more advanced instruments such as high-throughput gradient flash and medium or high
pressure liquid chromatography (HPLC). In general, methods of isolation can be divided into
a few categories including extraction, precipitation, and chromatography. Before the invention
of sophisticated analytical spectroscopy techniques such as nuclear magnetic resonance
(NMR), mass spectrometry (MS), infrared spectroscopy (IR), and X-ray crystallography,
determination of molecular structure of pure compounds from natural products had been the
major obstacle in drug development. People had been using different sets of chemical trans‐
formations and measurement of physical data such as melting point and molecular weight for
the compounds structure determination. Issues regarding chirality have been an on-going
debate among the scientists when deciding on the structure of the isolated natural compounds.
When Fischer and Daniel Koshland suggested the lock and key model and induced fit theory,
the chirality of natural compounds had become an important issue that needs to be resolved
before the real mechanism of action can be proposed. Since single target approach relies heavily
on the interactions between the bioactive compound and protein target; possibly specific
enzyme or receptor, the real identities of the natural compounds need to be accurately
determined. Nowadays, it is obligatory to include the proper and accurate structural elucida‐
tion data of the pure compounds before the pharmacological activity can be published in any
research journals. Such remarkable improvements in the spectrometry techniques have
definitely amplified the speed of drug discovery process from natural products. A single plant
extract may consist of a considerable pool of metabolites. Attempt to isolate the right bioactive
compound out of the hundreds mixture of other compounds is quite tedious and time
consuming; similar to finding a needle in a haystack. Two conventional approaches that
deserved a mention here are the extract-library screening and bioassay-guided isolation. These
two techniques, popularized in the 1980s, are commonly used for screening, hit identification,
and hit-to-lead development from the natural products, however received a competitive
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disadvantage when compared to the approaches using the synthetic chemical libraries [38].
The screening of extract-library normally carried out on cell cultures to study the cellular
responses under controlled conditions. The extract that shows certain activity will then be
subjected to a series of isolations until the pure active compound is obtained. A more recent
bioassay-guided isolation method requires a step-by-step separation of extracted components
based on differences in their physicochemical properties and assessing the biological activity
where the process continues until the right bioactive compound is successfully isolated. One
best example is the use of TLC plate, in which spraying with reactive media that respond with
the compounds from extract will produce a color implying the presence of an active compound
and further isolation work is required to obtain the compound. While these two methods are
in disadvantage position compared to the more well-defined high throughput screening on
synthetic chemical libraries, lately it received a renewed interest from both the academic
institutions and drug industries. The practicality of discovering new drugs by conventional
methods has been constantly receiving negative perception from the funding agencies and
private companies. Considering the number of people who actually have the access to high
throughput screening chemical libraries or other high throughput bioassays, authors truly
believe that the use of the aforementioned conventional methods are still highly relevant in
our society. Without a doubt, these old practices have definitely set a good platform in natural
products drug discovery program.
4. De-emphasize of natural products research in the 80’s
The interests in finding bioactive natural products from the tropical rainforests at several major
pharmaceutical companies had generally declined in the early 1980s when microorganisms
and fungi which were easy to collect and culture provided alternative sources. Dwindling
interests on plants as source of drugs were also due to low success rate in the discoveries of
plant-derived drugs, and advances in synthetic organic chemistry and biotechnology that
offered more opportunities to design new drugs in the laboratory [33, 39]. Many pharmaceut‐
ical firms had abandoned exploring traditional knowledge of plants in mid-1980s in their
search for new drugs.. The reductionist approach in finding bioactive natural products from
the tropical rainforests had declined due to the many major hurdles faced by them such as
difficulties in obtaining sufficient supply of high quality natural products screening libraries,
ownership issues and research in this field is lengthy, expensive, highly complex and ineffec‐
tive with low success rate. On the other hand, the process of drug development is often a risky
and costly endeavor. Drug discovery and development process requires between 10 to 20 years
and was estimated to cost US$ 802 million per drug in 2004 [40]. Most recently it was estimated
that the cost of inventing and developing a drug could exceed US$1 billion or more. The
average drug developed by a major pharmaceutical company costs at least $4 billion, and it
can be as much as US$11 billion [41]. Natural products drug discovery has been marginalized
in favor of the rational design of synthetic compounds to target specific molecules after the
advent of high throughput screening (HTS), combinatorial chemistry and advancement in the
knowledge of molecular mechanisms, cell biology and genomics.
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Historically numerous complications linked with natural products, particularly plant-derived
products, added to decreasing attention in their development within the pharmaceutical
industry. A few years ago, there were major problems with obtaining authentic plant materials.
Difficulty in the access to genetic resources and traditional knowledge by the multinationals
and pharmaceutical firms and the absence of a legal framework for a fair and equitable sharing
of benefits, arising from the commercial and other utilization of genetic resources with the
resource countries resulted in the departure of many drug companies from investing in natural
products from tropical rainforest plants as a source of drug leads. It was convenient to collect
plants and exhibit that their extracts possessed interesting biological potential. However, when
investigators returned to approve the potential and ultimately to develop and commercialize
the product, failure resulted often due to inadequate records and loss of the original collections
of plant. There were also problems regarding the assessment of biological activities of natural
products, which commonly are complex combinations of materials. The interactions among
the components of the mixtures, either the antagonism by a material of another’s activity or
the combined effect/addition of activities, often delivered unclear results. Identification and
purification of active components from intricate natural products encompassing lots of
numerous chemical substances, regularly of almost similar physical and chemical properties,
were slow and expensive. Once the active component was isolated and purified, its chemical
structure still needed to be documented. Moreover, natural product materials are often poor
pharmaceuticals; their chemical stability may be minimal; they might have poor solubility or
bioavailability characteristics; they may not formulate properly, etc., therefore not ensuing
Lipinski’s Rule of Five [42]. All these difficulties have stood stern challenges. The most
accountable problem for restricted importance in plant-based natural product materials for
pharmaceutical discovery and development has been hesitation regarding the availability of
amounts of pure chemical substances. Quantities are required initially to generate information
to understand and assess real prospective of the material for pharmaceutical application.
Ultimately, the most restrictive thought is the amount required to fulfill market demand should
a pharmaceutical develop into an effective drug. The market demand can vary from a scale of
hundreds to thousands of kilograms yearly. It is recognized that the complete synthesis will
not provide the intricate natural product to satisfy this market demand [43].
Subsequent to the ‘Golden Age of Antibiotics’ and the worldwide reassurance to discover new
antibiotics, several main pharmaceutical companies at the time initiated natural product
discovery (NPD) programs which highlighted not only on antifungal and antibacterial targets
but also on infectious illnesses. These platforms provided compounds for the treatment of
hypercholesteremia, tissue rejection in organ transplantations, cancer and microbial infections
[44, 45]. Though majority of the larger pharmaceutical industries removed their NPD programs
during the 1980s and early 1990s, it was the advent of programmed high throughput screening
(HTS) which enhanced the impetus of biological testing and combinatorial chemistry started
to be endorsed as a better method to producing ‘drug-like’ materials for HTS. As a result,
several pharmaceutical companies sold their gatherings of screening extracts [46, 47] as it was
believed that orthodox extract-derived monitoring resulted in the constant rediscovery of
previously isolated compounds and that the structural intricacy of natural products required
whole synthesis and derivatization which is both synthetically and economically difficult.
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Owing to supply difficulties, the time required to develop a natural product from an extract
to a pharmaceutical was believed to be excessively lengthy; HTS machineries rely on combi‐
natorial chemistry to yield huge compound libraries. During the past two decades ‘customary
natural product chemistry’ has predominantly been substituted by molecular target-based
drug discovery, using great combinatorial libraries to discover effective ‘hits’ [45]. However,
developments in technology and sophisticated instrumentation for the rapid identification of
novel natural products and structure explanation keep enhancing the natural product
discovery [44]. Since 1980s, it was thought that combinatorial chemistry would be the upcom‐
ing basis of numerous new carbon skeletons and drug front runners or novel chemical entities
(NCEs). This has unquestionably not been the case because there has only been one combina‐
torial NCE permitted by the U.S FDA in that time frame, the kinase inhibitor sorafendib
(approved by the FDA, 2005) to treat renal carcinoma [48]. Combinatorial chemistry has
definitely altered the progress of new chemical leads following in the synthesis of structural
analogues [48]. At that instance, combinatorial libraries included hundreds to thousands of
novel compounds; however through the late 1990s synthetic chemists came to know that these
libraries needed the intricacy of the complex natural products produced by nature [48]. The
idea of diversity-oriented synthesis (DOS) was applied in which synthetic chemists would
synthesize compounds analogous to natural products or that are based on natural product
topologies. These compounds are currently being verified in a large variety and number of
biological screens to define their role (s) as leads to new drug entities [48]. The examination of
the degree of NCEs authorizations shows that natural products still add to or are involved in
~50% of all small molecule testing from 2000–2006 [49]. This is endorsed by the statistical data
where out of 7000 natural compounds, 20 drugs have been discovered with a hit rate of 0.3%
whereas HTS of synthetic compound libraries only achieved below 0.001% hit rate. Nonethe‐
less the pharmaceutical industries have used considerable resources to both combinatorial
chemistry and HTS [49]. Of the 1184 NCEs covering all diseases/sources/countries, 30% were
discovered to be synthetic. It is also noteworthy that 52% of these compounds are whichever
a natural product, a chemical modification or a mimic of a previously existing natural product
pharmacophore [49]. Notwithstanding recompenses and the past accomplishments, majority
of large pharmaceutical companies have reduced the use of natural products in drug discovery
screening. This has been due to the apparent shortcomings of natural products and the
expectations related with the use of assortments of compounds prepared by combinatorial
chemistry approaches.
5. Revival of natural products research in the 90’s
However, there was a revival of traditional knowledge-driven drug development in the later
part of the eighties and this was partly due to the advances in chromatographic and spectro‐
scopic techniques which have had a tremendous impact on the isolation and structure
elucidation of the constituents of medicinal plants and the development of series of bioassay
methodologies which were fast, easy to perform, quantitative and could selectively detect
biologically active molecules at very low levels [50]. The phytochemicals can also be used as
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starting materials for the partial synthesis of drugs, as lead structures for molecular modifi‐
cation or as models to synthesize new drugs with improved therapeutic effects. In order to
conduct preclinical and clinical trials and further develop a promising lead into a marketed
drug, sustainable supply is necessary. The continuous supply problem is the major challenge
for plant natural product drug discovery and development. Nevertheless, contemporary
methodologies are accessible to overwhelm the difficulties. Advancement in technologies like
biotechnology, fermentation, total chemical synthesis, sampling strategies and nanoscale NMR
for structure determination are all vital to the accomplishment of natural products as drug
leads. The novelty in the field of natural products, will result in a new wave revival of novel
drugs in the upcoming future [51]. The past few years, though, have seen a reintroduced
attention in the use of natural compounds and, more significantly, their part as a basis for drug
development. The contemporary apparatus of chemistry and biology particularly, the
numerous ‘-omics' technologies now let researchers to detail the precise nature of the biological
effects of natural compounds on the human body, in addition to discover probable interactions,
which grasps much potential for the development of novel treatments against numerous
devastating diseases, including cancer and dementia. The recent revival of interest in natural
products research is mainly due to disappointing results of combinatorial chemistry and HTS
in delivering potent chemical leads. There is a new hope for the discovery of drug leads from
the tropical rainforests. One reason why natural products are advantageous is that they
provide complex molecules not accessible through synthesis. For example, taxol and rapamy‐
cin could not be synthesized cost effectively by standard medicinal chemistry, even including
combinatorial chemistry approaches. Combinatorial synthetic methods are unlikely to
produce molecules of the complexity of rapamycin and taxol.
Natural products have pointed the way to the future. A number of noteworthy advances in
science and industry have been inspired by the quest of capturing the value of natural products.
In 1982, the US National Cancer Institute began again to look for new drugs from the rainfor‐
ests. There are good reasons for such renewed interest because they have already provided
tangible evidence of their potential with remedies for a range of medical problems ranging
from childhood leukemia to toothaches. Some examples of rainforest plants responsible for 25
percent of the drugs used in the clinic are included in Table 1. Most developments in capability
and technology are nurturing a revival in natural products research and are either directly or
indirectly addressing the historical obstacles to development of natural products [52-56]. There
are three foremost reasons for the revitalization of natural product research; i). The potential
of combinatorial chemistry to fill drug development projects with de novo synthetic small-
molecule drug candidates is unsatisfied. ii). The applied problems of natural products drug
discovery are being overawed by advances in separation equipment and in the speed and
sensitivity of structure explanation. iii). A convincing case is being made for the essential
usefulness of natural products as foundations of drug leads.
Possibly the strongest motivation for development of new natural products is the improve‐
ment in bioassay technology over the last few years. We now have automatic, specific and
selective bioassays in which materials, comprising natural products preparations, can be
evaluated quickly and cost-effectively. In reality, although the bioassay technology develop‐
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ment facilitates faster and accurate substances evaluation, the availability of those evaluating
substances has become very limited. Once the biological activity has been confirmed by a
suitable bioassay or primary screen, the current separation and structure elucidation technol‐
ogy allow us to isolate, purify and determine the chemical structure of the active constituents
in few days, or at maximum, a few weeks. The development of separation methods are mainly
linked with high performance chromatography techniques [52]. The biodiversity of the earth
is quickly declining and we frequently come across many articles in newspapers and journals
on the rate, consequences, cause, etc., of loss of biological diversity. This will lead to the loss
of chemical diversity and loss of potential uses of those chemicals have for mankind. Besides
medicines, foodstuffs, fibers for clothing, building materials, etc. are chemicals derived from
nature. The loss of those important organisms and their respective chemical diversity is the
driving force for the revival of natural products research [56]. Globalization of world’s
economy increases the interest in pharmaceutical development. Since the discovery and
development of new pharmaceuticals help to uphold the competitiveness of the industry,
natural products research has been revisited as a way to increase the effectiveness of discovery
and development [55].
No Drug Origin Use
1 Quinine Cinchona tree (S. America) Treat malaria
2 Neostigmine Calabar bean (Africa) Used to treat glaucoma and provides a blueprintfor synthetic insecticides
3 Novacaine, cocaine Coca plant (South America) local less addictive anesthetics
4 Turbocurarine Curare liana (America)
Native people used to poison arrow tips.
Used as relaxants to treat muscle disorders like
Parkinson’s and Multiple Sclerosis.
5 Vincristine,vinblastine Rosy periwinkle (Madagascar) Hodgkin’s disease and Pediatric leukemia








Reverse transcript inhibitor (Anti HIV)
Reverse transcript inhibitor (Anti HIV-1, and
HIV-2)
Table 1. Drugs derived from rainforest plants
Many new approaches have been employed in the isolation and purification of NP, using
various advanced fractionation techniques which includes the counter-current chromatogra‐
phy [57, 58] and structure elucidation by spectroscopic techniques (1D, 2D NMR spectroscopy,
FTIR, UV, mass spectrometry, etc.) [59, 60]. The arrival of more compatible high-throughput
screening technique provided an opportunity to screen natural products mixture within the
quick span of time. Singh and Barrett [59] reported that pure bioactive compounds can be
isolated from fermentation broths in 2 weeks and that the structures of more than 90% of new
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compounds can be elucidated within 2 weeks. Advanced NMR techniques permit to solve
complex structures using less than 1 mg compound. Quinn et al. [61] showed that it was
possible to prepare a screening library for highly diverse compounds from plants from analysis
of the Dictionary of Natural Products, where the compounds were pre-selected based on drug-
like in their physicochemical properties. It will be interesting to see if such a collection proves
to be enriched in bioactive molecules. Besides the above, many alternative methods are also
being explored in efforts to increase the speed and efficiency of using natural products in drug
discovery. Multifaceted approach integrating traditional and modern techniques, i.e. combin‐
ing botanical, phytochemical, medicinal chemistry, HTS, organic and combinatorial chemistry
synthesis producing natural products-like compounds, biological, computational, molecular,
multi-target approach, metabolomics, proteomic and genomic techniques will continue
reviving the interest in using natural products as leads for the discovery of new drugs.
6. Modern approaches in drug discovery from natural products
The arrival of novel technologies in mass spectrometry, NMR and other spectroscopic
techniques, bimolecular target or cell-based screening, early hit characterization and the
utilization of computational methods have improved the impact of natural products in the
HTS based drug discovery. Natural product extracts frequently contain a large number of
constituents comprising those, which are difficult to separate. The unambiguous structures of
pure compounds can be determined by the combination of conventional techniques like
ultraviolet absorption spectroscopy (UV), IR, MS and NMR. In rare cases, where there is a
difficulty in determining the absolute configuration, the single crystal X ray analysis is
employed. The conventional separation techniques are time consuming and tiresome. The
direct hyphenation of a proficient separation technique with efficient spectroscopic techniques
such as HPLC-FTIR can be used to support the dereplication process [62]. HPLC-FTIR has been
used to detect functional groups in main constituents of mixtures but has not found extensive
application owing to limitations in compatibility; i.e. obtaining optimum separation accom‐
panied by adequate detection [62].
One of the new technologies in drug discovery from natural products is the use of capillary
electrophoresis (CE) in screening program first developed by Cetek Corporation and Cubist.
The assay is able to identify active natural product compounds/ extracts and by detecting any
shift in the protein when a ligand binds to it due to the conformational and surface charge
changes. The CE technique can distinguish between weak and strong binding compounds in
extracts prior to determining their concentration [63]. This technology has been applied to
Cetek’s internal drug discovery program in finding novel natural product compounds that
inhibit the cancer target, HSP90, a molecular chaperonin that is responsible for maintaining
the correct folding and stability of proteins [64]. Another interesting example which was
recently reported by Wang, et al.showed that a CE method in conjunction with liquid chro‐
matography-tandem mass spectrometry (LC-MS/MS) has been successfully applied in the
screening of plant extracts, successfully identified a natural compound called baicalin from
Radix scutellariae as a new protein kinase an inhibitor [65]. In an another separate study, Zhao
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and Chen, developed a simple and effective neuraminidase-immobilized capillary microreac‐
tor facbricated by glutaraldehyde cross-linking technology for screening of the neuraminidase
inhibitors from traditional Chinese medicines. Six out of eighteen natural products including
bavachinin, bavachin, baicalein, baicalin, chrysin, and vitexin have been found as potent
inhibitors from the screening[66]. Some important aspects of CE that deserve a recognition in
this chapter is its ease of use, versatility and high resolution separation components, high
separation efficiency, and its low amount of sample and reagent consumption.
Flow injection analysis-NMR (FIA-NMR) encompasses a sample, which is injected as a plug
into a fluid stream and then swept into the NMR detector coil. In a FIA-NMR, the mobile
phase is  used as a hydraulic  push solvent which transfers the injected sample from the
injector port to the NMR flow cell. The scout scan that is used to determine the location of
the solvent peaks is obtained by the spectrometer once the pump stops. Finally a signal is
sent to the solvent pump so that the old sample from the NMR flow-cell can be flushed
out [67]. HPLC-NMR-MS is a novel and most advanced spectrometric method that is used
in  the  de-replication  of  natural  product  extracts  [68].  Despite  being  the  most  effective
method, the benefit of the above said hyphenated methodology is the matching of the MS
data  to  the  NMR spectrum.  In  addition,  the  information  of  the  functional  groups  (e.g.,
hydroxyl and amino moieties) that are delivered by the HPLC-NMR is readily identified
by MS techniques. The advent of higher field magnets and cryo probes had proven HPLC-
NMR to be a strong and effective spectroscopic instrument and applied to the crude extracts
(NMR and UV profile from PDA HPLC detection). There is a significant improvement in
the  profiling  sensitivity  and de-replication  of  natural  products  due  to  the  utilization  of
higher  field  magnets  and  the  recent  developments  of  the  micro  coil  HPLC-NMR  and
capillary  NMR  (CapNMR)  which  has  allowed  for  smaller  amounts  of  samples  to  be
examined in the order of 40–120 µL [69-71]. The micro coil HPLC-NMR is best suited for
online  HPLC-NMR which uses  the  on flow,  stop flow or  time silencing experiments  to
separate  components  present  in  greater  concentrations  and  analyses  the  same  [71-74],
whereas the Capillary NMR uses the non-deuterated solvents in an off-line HPLC separa‐
tion thereby offering a wide range of solvents with a low cost. The isolated compounds are
re-dissolved in deuterated solvents and then injected into the CapNMR flow probe using
volumes of around 6 µL with 1H-NMR spectra acquired for sample quantities in the order
of 2–30 µg, thereby increasing the sensitivity with a prospect to classify the novel low level
secondary metabolites [75].
Besides the above, the information obtained from the 1D and 2D NMR spectra is sufficient to
classify the compounds in addition to the provision of a ‘high-fidelity’ snapshot of the
constituents in the extract, thus providing the information which paves way for rational
decisions about the top method of fractionation or to proceed with isolation further. Many
recent publications have been reported using this approach [71-73].The technique and
utilization of HPLC-NMR in natural products identification/classification is well recognized
in the literature but applications of its uses have mainly dealt only with the chemical profiling
of plants [76-78]. Numerous modes of HPLC-NMR (mostly on-flow and stop-flow modes)
combine the resolving power of chromatography, which is interfaced with the structural
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understanding provided by NMR. The reductionist approach has not been very successful in
discovering effective drugs to treat complex diseases, such as cancer, metabolic, cardiovascular
and neurological diseases. Single-target drugs may not always induce the desired effect to the
entire biological system even if they successfully inhibit or activate a specific target.There are
limitations in the use of reductionist or mono-target approach in drug discovery. The approach
yields only a limited understanding of complicated pathogenesis and multi-target pathologies
of systemic diseases such as cancers, cardiovascular diseases and neurodegenerative disorders.
There is difficulty in identifying relevant interventions to target such complexities. Bullet-
based or mono-target drug intervention cannot effectively combat the complex pathologies of
systemic diseases as they are regulated by complex biological networks and depend on
multiple steps of genetic and environmental challenges to progress. Recently there is a growing
interest to use innovative approaches to drug discovery from natural products by network
pharmacology which integrates systems biology and pharmacology [79]. The integrated
multidisciplinary concept of multiple targets, multiple effects and complex diseases in network
pharmacology have enriched our understanding of complicated pathogenesis and multi-target
pathologies of systemic diseases and reduced difficulty in identifying relevant interventions
to target such complexities. The ‘-omic’ technologies in system biology have now been widely
used to correlate and elucidate multiple targets and network of human diseases and drug
actions [80]. The concept of network pharmacology is especially useful in accurately translating
and interpreting the therapeutic effects of herbal medicines into modern biochemical and
biological meanings. Herbal medicines may serve as valuable resources for network-based
multi-target drug discovery. The concept of network pharmacology is especially useful in
accurately translating and interpreting the therapeutic effects of herbal medicines into modern
biochemical and biological meanings. The efficacy of the multi-target drugs from herbal
extracts are developed followed by identification of their major bioactive components and
redevelopment of a completely new multi-component formulations composed of the major
bioactive components in order to reach a synergistic and optimal combination [81].
Combining natural product chemistry and metabolomics approaches in drug discovery is a
new strategy to discover new drugs. There are few reports in the scientific literature, which
discuss the unison of classical natural product chemistry approaches with metabolomics to
identify novel bioactive natural products. These have generally focused on the study of plants
[82]. The identification of bioactive natural products from plants remains a multifaceted task
because of their high chemical diversity and complexity. By measuring the metabolome of
different extracts or fractions of a plant and combining these data with its corresponding
biological activity, signals related to the compounds related to the displayed activity can
potentially be determined. Systems biology is a most promising field encompassing tools in
the post-genomics revolution such as transcript omics, proteomics, glycomics and fluxomics
with an intention to characterize all gene and cell products completely inclusive of mRNA,
proteins, glycan structures and metabolites. Metabolomics aims at constructing balanced
observations using highly reproducible tools followed by the analysis of data to locate the
correlations between the available data. The profiling of all the low molecular weight metab‐
olites of an organism is not possible and hence this emerging field of metabolomics combines
analytical chemistry, biochemistry and computational biology permitting the analysis of
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thousands of metabolites in any biological system. The principal analytical platforms are the
Mass spectrometry with gas chromatography (MS-GC), liquid chromatography (LC) or
capillary electrophoresis (CE) and NMR spectroscopy. A balanced extraction procedure to
efficiently extract all the primary and secondary metabolites from tissues and the body fluids
is used to obtain them in the natural form prior to the analysis in the various solvents used.
The metabolite extraction procedures are more complicated and complex due to the diversified
nature of small molecules present and due to the unavailability of a single analytical technique
and platform which helps in analysis of all the metabolites simultaneously. Several separation
techniques and methodologies need to be applied to achieve complete analysis of the metab‐
olites [83]. Simultaneous analysis of hundreds of compounds is achieved by various tools in
informatics that extracts information from the data, removing the background noise, detection
and integration of peaks throughout large data sets and normalizing and transforming the
resulting data matrices prior to any statistical analysis [84]. Metabolomics has a restricted
access to the ability of identifying the signals with respect to the chemical nature. About 60 to
80 % of all detected compounds are unknown [84-85] even today and the metabolic discipline
has created a large mass of spectral NMR library to tackle this problem. These unknown
secondary metabolite structures can be one among the undiscovered resources of the natural
products, fingerprinting, foot printing, profiling or target analyses are common terms used in
this field. Fingerprinting aims to take a ‘snapshot’ of the organism where the signals cannot
necessarily be used to detect/identify specific metabolites and depends strongly on the
technique used. The signals are assigned to a metabolite irrespective of its nature to be a known
or a novel compound. The term target analysis aims to determine and quantify a specific
metabolite of interest [81].
The microarray is a new technology recently developed that has empowered the scientif‐
ic community to understand the fundamental aspects underlining the growth and develop‐
ment of life as well as to explore the genetic causes of anomalies occurring in the functioning
of the human body.DNA microarray technology can analyze and compares changes in DNA
or protein.  A chromosomal change in an abnormal individual  could be identified when
DNA from this individual is compared with DNA (control) from a healthy individual. It
is very precise and useful in that it is capable to detect much smaller changes compared to
conventional karyotyping technique. This competent technique enabled us to understand
the elemental aspects underlining the growth and development of life as well as to explore
the genetic causes of anomalies occurring in the functioning of the human body. Microar‐
ray  technology  has  been  utilized  extensively  in  pharmacogenomics  where  comparative
analysis of the genes from an unhealthy and a normal cell will help the identification of
the biochemical constitution of the proteins synthesized by the abnormal/unhealthy genes.
The information obtained from the analysis then could be utilized for synthesis and design
of  drugs  which  fight  the  abnormal  proteins  and  reduce  their  effect  [86].Kwon  and  his
colleagues  have  developed  an  in  vitro  approach  utilizing  a  multi-enzyme  containing
microarray system for high-throughput synthesis of polypeptide derived product and their
subsequent full polyketide-based library screening of the human tyrosine kinase (TK), on
a single glass microarray. The TK inhibitors are expected to treat chronic myeloid leuke‐
mia, gastrointestinal stromal tumours and breast cancer [87, 88].
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A drug discovery program aims to find novel bioactive natural products, which possess some
form of potent biological activity. However the isolation of known and undesirable natural
products with no pharmacological interest or chemical is inevitable. The term dereplication
which is a process of identifying known compounds responsible for the activity of an extract
prior to bioassay-guided isolation becomes popular among the natural products researchers
[89, 90]. Dereplication strategies generally involve a combination of bioassay, separation
science, spectroscopic methods, and database searching and can be regarded as chemical or
biological screening processes. There are a number of ways in which natural product programs
approach dereplication, which is based upon availability of screening methods/instrumenta‐
tion, time and the cost to identify possible ‘biological leads or novel compounds’ from a crude
extract. At present there are many advanced methodologies and protocols that distinguish
novel entities from known natural compounds at an early stage of a drug discovery program
or in a natural product isolation strategy [90]. The dereplication process can be easily done by
screening the compounds through the commercially available databases, reducing the time
taken for structure elucidation of known compounds. One example is the Chapman and Hall
Dictionary of Natural Products [91]; The Dictionary of Marine Natural Products (on-line)
(subset of the Dictionary of Natural Products) containing over 30, 000 compounds [92];
MarinLit- The Marine Natural Products Database containing up to date bibliographic data on
marine organisms with the number of references from 1, 200 journals/books and data for ~21,
000 compounds [93]; AntiMarin is a more recent database, in which the number of methyl
groups, the number of sp3-hybridised methylene or methine protons, alkene, acetal, ether and
formyl groups can be searched [94, 95]. Besides, SciFinder Scholar and SCOPUS are important
research discovery tools (Chemical Abstracts on-line) [96, 97] and NAPRALERTTM is a
database of all natural products, including ethnomedical information, pharmacological/
biochemical information of extracts of organisms in vitro, in situ, in vivo, in humans (case
reports, non-clinical trials) and clinical studies [98]. The availability of these scientific databases
such as the ones mentioned to the research and academic institutions, is a fundamental and
crucial step in a well-governed natural product program. With the rise in the number of novel
drug targets, computational methods such as high throughput virtual screening, ligand
docking tools, ADME (absorption, distribution, metabolism and excretion) profiling and other
modern computational tools and softwares have been applied to accelerate the drug discovery
process. Some of the common natural products libraries and databases as listed below allow
the prompt screening of large number of natural compounds to be done in short period of time
against a variety of drug targets. Dictionary Of Natural Products (http://dnp.chemnetbase.com/
intro/index.jsp); UCSD Marine Natural Products Database (http://naturalprod.ucsd.edu/); Natural
Products Alert (http://napralert.org/) ; ZINC (http://zinc.docking.org/browse/catalogs/natural-
products) ; InterBioScreen (http://www.ibscreen.com/products.shtml); AnalytiCon Discovery
(http://www.ac-discovery.com/); Molecular Diversity Preservation International (http://
www.mdpi.org/). Computer-generated models of proteins including novel enzyme and receptor
targets apart from the protein crystal structures that are deposited in Protein Data Bank (http://
www.pdb.org/) can be easily generated by homology modeling subsequently followed by
simple molecular docking to examine the interactions between the natural compounds and
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the protein targets. Bioassays can then be conducted selectively on the natural hits or leads
retrieved without the neccesities of wasting the precious amount of the compounds and avoid
expensive and time consuming experimental methods. Examples of molecular docking
softwares currently available are AutoDock, AutoDockVina, FlexX, FRED, GOLD, eHiTS, and
Lead finders. Some examples using high throughput virtual screening including the work of
Wang et al. where ten natural compounds have been successfully identified as flacipain-2
(FP-2) inhibitors [99] and Liu et al. who have identified a natural product-like STAT3 dimeri‐
zation inhibitor by structure-based virtual screening [100].
Other  bioinformatics  tools  such as  ligand and structure-based pharmacophore screening
have also been reported to be successful in assisting the process of drug discovery from
natural  products.  Chen et  al.  have  proposed a  three-dimentional  quantitative  structure-
activity  relationship  pharmacophore  model  based  on  known  mTOR  inhibitors.  Virtual
screening using the best pharmacophore model successfully retrieved 20 natural products
as potential mTOR inhibitors scaffolds[101]. It is also important to mention here that from
the previous study by Doman showed that out of 365 molecules suggested by docking, 127
(34.8%) of them inhibited the activity of enzyme protein tyrosine phosphatase-1B (PTP1B)
while only 85 (0.021%) out of approximately 400, 000 molecules were retrieved from high-
throughput  experimental  assay.  That  is  around  1700-fold  enrichment  of  hit  rate  from
structure-based docking over random screening [102].On the other hand, incorporation of
chemoinformatic tools in drug discovery from natural products allow the compounds to
be screened for their ADMET (absorption, distribution, metabolism, excretion, and toxicity)
properties before they are enrolled in any drug development programs. Screening of natural
compounds using the Pfizer ‘Rule of 5’  allows the researchers to remove any molecules
that  do  not  obey  the  rules.  Since  these  rules  were  derived  from  a  set  of  experimental
observations of thousands of known drugs and drug-like molecules,  a trained medicinal
chemist/biochemist can easily use the in silico  data as a guide in determining the poten‐
tial  drug-like natural  compounds followed by the synthesis of further analogues so that
they would have a favorable drug-like properties. A good drug-like molecule in general
obey the following rules (i) molecular weight ≤ 500, (ii) calculated logP ≤ 5, (iii) number of
hydrogen  bond  donors  ≤  5,  and  (iv)  number  of  hydrogen  bond  acceptors  ≤  10.  The
introduction  of  in  silico  screening  and  natural  products  facilities  for  high-throughput
screening in  academic  labs  as  well  as  in  drug companies  reduce the  cost  from random
screening of very large collections of compounds. In silico or virtual screening helps to filter
down the number of compounds used in real screens [103]. On the other hand, bioinformat‐
ic tool such as the Dictionary of Natural Products gives structural information on 150, 000
different  compounds  that  could  be  used  in  virtual  screening,  even  though  the  com‐
pounds would still  have to be physically available for any predicted activity to be con‐
firmed through testing in a relevant assay. Finally, clustering of chemically related scaffolds
can be very useful in guiding the synthesis of new compounds, but obviously there is a
delay and expense in the synthesis.
An academic collaboration has established the Drug Discovery Portal (see http://
www.ddp.strath.ac.uk/) in an attempt to combine the techniques of virtual screening of
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chemically diverse natural products and their synthetic analogues with the rapid availability
of physical samples for testing, This allows a wide variety of compounds from academic
laboratories in many different institutions in a database that can be used for virtual screening.
Academic biology groups also propose new and novel protein structures as targets for virtual
screening with the Portal’s database (and with conventional commercially available databas‐
es). When hits are predicted from the in silico screening, the compounds can be obtained from
the originating chemist for confirmatory tests. Often, there is an immediate link to expertise
for the preparation of analogues to help start a lead optimization program. Nevertheless, access
to the Portal is freely available for the academic group. The continued expansion of the
chemical database means that there is a valuable and growing coverage of chemical space of
many novel chemical compounds. Although the compounds in the Portal’s database will
generally have already been disclosed in a thesis or in a chemistry journal, very few of them
have been previously tested for biological activity. This is a common feature of known natural
products: of the 150, 000 structures in the CRC Dictionary of Natural Products only 1% of them
have been investigated. The introduction of metabolomics technologies in natural product
discovery processes will be beneficial on multiple levels. By increasing the number of identi‐
fications in our metabolomics data, compounds with novel structures can be easily obtained
and tested for any disease under investigation. Furthermore, multi-parallel analysis using
metabolomics technologies will also enhance the throughput of chemical characterization
processes of many different species from natural resources. Since natural product chemists
have collected a lifetime of compound libraries of active and also inactive pure compounds,
these data can be used to construct the mass spectral and NMR spectral libraries, undoubtedly
help the biological interpretations of metabolomics data to be done with less difficulty. The
advancements in analytical instrumentation and sophisticated hyphenation of separation
techniques with high sensitive detectors have allowed for greater detection of small molecule
compounds measurable in biological systems (i.e., primary and secondary metabolites). These
technologies can be used to advance the discovery of natural product chemistry to identify
potential novel drugs candidates which will assist in sustaining health and the fight against
disease and illness. In the case of NMR of crude extracts, patterns can be easily visualized and
interpreted using the multivariate data analysis. This can be carried out in a comparative
manner distinguishing differences between relatively similar extracts or it can be linked with
a specific (generally in vitro) biological activity. Ultimately this enables the construction of a
complex database of the metabolome [104-106].
7. Scientific interests and recent advances in natural products research from
the tropical rainforests
Plant derived natural compounds have continuously captivated scientists globally on grounds
of being biocompatible, and are considered as potentially safe and effective therapeutic agents.
Table 2 shows examples of natural products derived from plants that have become well known
pharmaceuticals [107-116].
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No. Drug/Chemical Action/Clinical Use Plant Source
1 Betulinic acid Anticancerous Betula alba
2 Bromelain Anti-inflammatory, proteolytic Ananascomosus
3 Camptothecin Anticancerous Camptothecaacuminata
4 (+)-Catechin Haemostatic Potentillafragarioides
5 Cissampeline Skeletal muscle relaxant Cissampelospareira
6 Codeine Analgesic, antitussive Papaver somniferum
7 Colchicine Antitumor agent, anti-gout Colchicum autumnale
8 Curcumin Choleretic, Antitumor agent Curcuma longa
9 Demecolcine Antitumor agent Colchicum autumnale
10 Deserpidine Antihypertensive, tranquillizer Rauvolfiacanescens
11 L-Dopa Anti-parkinsonism Mucunasp
12 Digoxin Cardiotonic Digitalis purpurea
13 Etoposide Antitumor agent Podophyllumpeltatum
14 Glasiovine Antidepressant Octeaglaziovii
15 Irinotecan Anticancer, antitumor agent Camptothecaacuminata
16 Kheltin Bronchodilator Ammivisnaga
17 Monocrotaline Antitumor agent (topical) Crotalaria sessiliflora
18 Neoandrographolide Dysentery Andrographispaniculata
19 Podophyllotoxin Antitumor anticancer agent Podophyllumpeltatum
20 Quinine Antimalarial, antipyretic Cinchona ledgeriana
21 Qulsqualic acid Anthelmintic Quisqualisindica
22 Sanguinarine Dental plaque inhibitor Sanguinariacanadensis
23 Scopolamine Sedative Datura species
24 Sparteine Oxytocic Cytisusscoparius
25 Taxol Antitumor agent Taxusbrevifolia
26 Teniposide Antitumor agent Podophyllumpeltatum
27 Tetrandrine Antihypertensive Stephaniatetrandra
28 Theophylline Diuretic, brochodilator Theobroma cacao and others
29 Topotecan Antitumor, anticancer agent Camptothecaacuminata
30 Trichosanthin Abortifacient Trichosantheskirilowii
31 Vinblastine Antitumor, Antileukemic agent Catharanthusroseus
32 Vincristine Antitumor, Antileukemic agent Catharanthusroseus
33 Scopolamine Sedative Datura species
34 Taxol Antitumor agent Taxusbrevifolia
Table 2. Natural products derived from plants [107-116]
7.1. Anti-inflammatory agents
Natural products (and conventional medicines) offer great anticipation in the identification of
bioactive compounds and their development into drugs for the treatment of inflammatory
diseases. Plants have been the source of several conventional medicine systems through the
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world for centuries and continue to deliver mankind with new medicines to treat anti-
inflammatory conditions. Previously, the plant-derived medicines were dispensed in the form
of crude drugs like tinctures, teas, powders, poultices, and other herbal preparations. This
eventually serves as the basis of the current modern drug discovery [117]. Numerous records
can be found in conventional medicine concentrating on the relief from pain and inflammation.
People who are suffering from inflammation in the ancient times were treated with phyto‐
chemicals eventually lead to the discovery of the first anti-inflammatory, analgesic drug
aspirin. The discovery of aspirin was based on the previously known analgesic and antipyretic
features of the bark of willow-tree since 400 BC by the Greeks and Romans. In 1899, aspirin or
also known as acetylsalicylic acid was introduced as the first potent drug for the treatment of
rheumatic disease [118]. Hippocrates said ‘let your food be your medicine’. Another very well
studied natural anti-inflammatory agent is curcumin which is derived from the turmeric root.
Turmeric is a yellow spice intrinsic to Asia, commonly relished as both a food and a dye.
Turmeric appears as yellow in curry powder, and is a viscous compound found in turmeric
rhizomes. Many scientific reports have shown that curcumin exhibits strong anti-inflamma‐
tory powers and extremely effective at relieving pain, and most important of all it is nontoxic.
Like the NSAID’s, curcumin inhibits the pro-inflammatory mediator cyclo-oxygenase-2
(COX-2) although it is not selective to a single isoform. Besides, curcumin also affects the
activity of other important factors in inflammation such as NF-kappa β, PPAR Gamma
transcription factors, and 5-LOX [119]. By inhibiting the activity of all these features of
inflammation, curcumin delivers much superior anti-inflammatory and pain-relieving activity
than most drugs.
Ginger root which is a common spice found in food, also comprises a number of scientifically
confirmed pain relieving mediators. Ginger consists a protein-digesting enzyme called
zingibain, which seems to relieve arthritis pain by reducing inflammation. In reality, the anti-
inflammatory activity of ginger relates positively with aspirin. Ginger root also contains two
groups of compounds called as the shagaols and gingerols. These compounds are strongly
antioxidants, therefore serving to stop cells from untimely destruction because of exposure to
environmental toxins and by-products of metabolism. Still more, these compounds are strong
anti-inflammatory agents, and are recognized to relieve inflammation throughout the body
[120]. Provided that oxidation and inflammation are part and parcel of all chronic degenerative
diseases, ginger can play an important role in disease risk reduction. On the other hand, plants
such the Amazon bark cats’ claw and the common spice rosemary are also found to exhibit
potent anti-inflammatory and pain-relieving characteristics. In toxicity studies, these plants
were proven to be highly nontoxic. Besides, plants such as hops also contain well known anti-
inflammatory mediators. This herb is commonly found in beer brewing, comprises a group of
compounds called the humulones which were shown to inhibit phorbol ester-induced COX-2
expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and
c-Jun-N-terminal kinase as respective potential upstream targets [121].
Propolis has been used in folk medicine for thousands of years and gain wide recognition for
its possible therapeutic uses, because of the wide range of the biological and pharmacological
activities. Among the well-known and one of the major properties the anti-inflammatory effect.
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Though there are good numbers of studies focused on the biological activities of propolis
together with its botanical sources, studies on Chinese propolis are insufficient. The anti-
inflammatory effects of the ethanol extracts from Chinese propolis (EECP) and poplar buds
(EEPB) from Populus canadensis were investigated in vitro for their modulating effects on the
RAW 264.7 cells and the inflammatory cytokines production and by measuring nuclear factor
(NF)-κB activation in TNF-α or IL-1β stimulation HEK 293 cells using reporter gene assays.
Their possible modulatory effects on LPS-induced endotoxemia and acute pulmonary damage
as acute inflammatory signs were also tested in mice. Both Populus Canadensis EECP and EEPB
displayed a strong free-radical scavenging action and significant in vitro anti-inflammatory
effects by modulating key inflammatory mediators of mRNA transcription, inhibiting the
production of specific inflammatory cytokines, and blocking the activation of nuclear factor
(NF)-κB [125]. A group of scientists investigated the antioxidant capacities and anti-inflam‐
matory activities of ethanol extracts of leaves of Cassia alata, Eleusine indica, Carica papaya,
Eremomastax speciosa and the stem bark of Polyscias fulva, collected in Cameroon. The ethanolic
extracts displayed robust antioxidant activities against both hydrogen peroxide and superox‐
ide anion reactive oxygen species. The highest antioxidant activities was observed with the
Cassia alata. The effect of plant extracts on γδ T cells and in DC was evidenced by the dose
dependent reduction in TNF-α production in the presence of Cassia alata, Carica papaya,
Eremomastax speciosa Eleusine indica, and Polyscias fulva. γδ T cells proliferation was affected to
the greatest extent by Polyscias fulva [126].Celastrus paniculatus Willd., an important medicinal
plant widely used in Ayurveda, is enriched with remarkable nervine, cognition enhancing,
and other therapeutic properties. Antioxidant and anti-inflammatory activities of the aqueous,
methanol, and chloroform extracts of C. paniculatus seeds were evaluated using DPPH radical
scavenging assay, Trolox equivalent antioxidant capacity (TEAC), Ferric reducing antioxidant
power assay (FRAP), and lipoxygenase inhibition assay, respectively. Total phenolic content
was also determined. Almost all the assays suggested chloroform extract to have the strongest
antioxidant property and the highest phenolic content. However, aqueous extract showed
maximum anti-inflammatory activity [127].
7.2. Anticancer agents
Plants have a long history of use in the treatment of cancer. The medicinal herbs that are
traditionally used for anti-cancer treatment and that are anti-angiogenic through multiple
interdependent processes (including effects on gene expression, signal processing, and
enzyme activities) include Goniothalamus species (Custard-apple family), Artemisia annua
(Chinese worm wood), Viscum album (European mistletoe), Curcuma longa (curcumin),
Scutellaria baicalensis (Chinese skullcap), resveratrol and proanthocyanidin (grape seed
extract), Magnolia officinalis (Chinese magnolia tree), Camellia sinensis (green tea), Ginkgo biloba,
quercetin, Poriacocos, Zingiber officinalis (ginger), Panax ginseng, Rabdosia rubescens hora
(Rabdosia), and Chinese destagnation herbs [128]. The exploration of anticancer agents from
plant sources has started since the 1950s. More than 3000 plants species have been reported to
be involved in the development of anticancer drugs [129]. Numerous compounds from tropical
rainforest medicinal plant species with potential anticancer activity have been identified.
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Positively, most of the new plant secondary metabolites and their derivatives have been
utilized in clinical cancer trials [130-132]. Of all available anticancer drugs between 1940 and
2002, nearly half were natural products or their derivatives with another 8% considered natural
product mimics [131]. The anticancer agents from plant origin which are currently in clinical
use can be classified mainly to four classes: the first class is the vinca alkaloids e.g. vincristine,
vinblastine, vindesine, vinorelbine; second class the podophyllotoxin and its derivatives which
includes etoposide, teniposide; the fourth is taxanes under which come the paclitaxel, doce‐
taxel and the fifth class is the camptothecin and its derivatives (e.g. topothecan, irinothecan).
Other groups include anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin). As
a matter of fact, half of the anti-cancer drugs which are globally accepted and in use today
were either natural products or their derivatives and were developed based on of knowledge
gathered from naturally existing small or macromolecules [133, 134]. In addition to this there
is numerous active biomolecules identified in fruits and vegetables and can used in anticancer
treatment. These agents include the curcumin which is mainly isolated from turmeric,
resveratrol found in red grapes, peanuts and berries, the genistein exist in the soybeans, the
diallyl sulfide and S-allyl cysteine in allium, the allicin of garlic, the lycopene in tomato, the
capsaicin in red chilies, beside the diosgenin in fenugreek, 6-gingerol in ginger, ellagic acid in
pomegranate, ursolic acid naturally found in apple, pears, and prunes. Similarly the catechins
in green tea, eugenol in cloves, indole-3-carbinol in cruciferous vegetables, and beta carotene
in carrots [128, 135].
Vinblastine and vincristine were isolated from Catharanthus roseus (L.) G. Don (Apocynaceae)
(formerly Vincarosea L.) and have been used clinically for over 40 years[136]. The vinca
alkaloids and several of their semi-synthetic derivatives block mitosis with metaphase arrest
by binding specifically to tubulin resulting in its depolymerization [137]. Podophyllotoxin was
isolated from the resin of Podophyllum peltatum L. (Berberidaceae) but was found to be too toxic
in mice so derivatives were made with the first clinically approved drug being etoposide [138].
The epipodophyllotoxins bind tubulin, causing DNA strand breaks during the G2 phase of the
cell cycle by irreversibly inhibiting DNA topoisomerase II [138]. Paclitaxel was originally
isolated from Taxus brevifolia Nutt. (Taxaceae) and was clinically introduced to the U.S. market
in the early 1990s [139, 140]. The taxanes, including paclitaxel and derivatives, act by binding
tubulin without allowing depolymerization or interfering with tubulin assembly [141, 142].
Camptothecin was isolated from Camptotheca acuminata Decne. (Nyssaceae) but originally
showed unacceptable myelosuppression [139, 143]. Interest in camptothecin was revived when
it was found to act by selective inhibition of topoisomerase I, involved in cleavage and
reassembly of DNA [143]. The taxanes and the camptothecins together account for approxi‐
mately 30% of the worldwide accepted and marketed anticancer drugs in 2002, costing over
US$ 2.75 billion [143]. Besides these, irinotecan was isolated from the same Camptotheca
acuminata tree in China for metastatic colorectal cancer and 9AC for ovarian, stomach cancer,
and T-cell lymphoma. Like camptothecin, this drug is also currently in clinical trials and have
already been approved by the FDA [144]. Numerous derivatives of all four compound classes
have been synthesized, some of which are currently in clinical use. All of these natural products
have led to significant biological discoveries related to their unique mechanisms of action.
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7.3. Immunomodulatory agents
Immunomodulators are used to enhance or suppress host defense responses in the treatment
of those diseases in which defective immune responses play an important role in determining
disease outcomes. These include primary and secondary immunodeficiencies that accompany
long-standing infections, as well as debilitating diseases like cancer, rheumatoid arthritis,
systemic lupus erythematosus and long-standing infections, leading to acquired immune
deficiencies. Immunosuppressive drugs are commonly used in the treatment of inflammation
and allergic disorders and rejection of transplanted organs, while immunostimulant drugs are
highly desirable for the treatment of immunodeficiency and infectious diseases [145]. Many
therapeutic effects of plant extracts have been recognized and recommended based on their
impact on human immunity [146]. A good numbers of herbal preparations such as Phyllanthus
debelis, Tinospora cordifolia, Trogonella foenumgraecum, Pouteria cambodiana, Centella asiatica,
Panax ginseng and Picrorhiza scrophulariiflora have been found to display a wide range of
immunomodulatory effects [147-150]. The idea of modulation of the immune response to
relieve the diseases has existed in early system of medicine together with Ayurveda and Unani.
Additionally, plants have been widely used as a source of medicine in these systems to support
health and to uphold body’s resistance against infections [151]. Phytochemicals such as
polysaccharides, lactones, alkaloids, diterpenoids and glycosides, isolated from several plants
have been reported to contain potential immunomodulatory agents [151, 152]. Several types
of immunomodulators have also been identified from isolates and extracts of bacteria and
fungi, mammalian proteins such as interferons, interleukins and cytokines and some synthetic
chemicals [153]. Several types of immunomodulators have been identified, including isolates
and extracts of bacteria and fungi, mammalian proteins such as interferons, interleukins and
cytokines and some synthetic chemicals [153]. Natural products and their derivatives represent
a new class of novel immunomodulating agents. However, only little information is available
about the immunological effects exerted by medicinal plants from the tropical rainforests
which have been used traditionally for treatment of various ailments.
Plants belonging to family Meliaceae, such as, Azadirachta indica, Mumronia pumila, Melia
azedarch, Cedrela lilloi and Trichilia elegans etc. show strong anti-inflammatory and anti-
rheumatic properties [154] C. lilloi and T. elegans constrained the phagocytic capability and
oxidative metabolism by opsonized zymosan as stimulus in peritoneal macrophages [155].
Lima et al. [156] reported that Pisumsativum agglutinin (PSA) prompts immunomodulatory
effects by activating spleen lymphocytes in vivo. Our previous study on the screening of 20
medicinal plants for their phagocytic properties have indicated that the methanol extracts of
some plants including Phyllanthus amarus exhibited strong immunomodulatory effects on
polymorphonuclear neutrophils and macrophage cells [157]. The standardized methanol
extracts of P. amarus and P. urinaria and their biochemical markers phyllanthin and hypophyl‐
lanthin, were able to modulate the innate immune response of phagocytes especially on the
chemotactic migration of phagocytes, phagocytic ability and on the release of reactive oxygen
species (ROS) [158]. The withanoloid, coagulin-H from Withania coagulans was found to have
extremely potent IL-2 inhibitory activity. A complete suppression of PHA-activated T-cell was
observed at 2.5 µg/mL concentrations and this suppression activity was similar to that of
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prednisolone. Similarly the IL-2 production was inhibited (IC50 = 0.35 mg/mL). Molecular
docking technique revealed the better interaction of coagullin-H at amino acids at the receptor
binding site of the IL-2 protein compared with prednisolone [159]. The natural compound
cheiradone, from a Euphorbia species was identified to interfere with angiogenesis process,
inhibiting the in vivo and in vitro vascular endothelial growth factor (VEGF) in stimulated
angiogenesis process. All stages of VEGF-induced angiogenesis were inhibited with an IC50
values that range between 5.20 and 7.50 µM. In addition to this activity it inhibited VEGF
binding to VEGF receptor-1 and 2 with IC50 values of 2.9 and 0.61 µM respectively. However,
cheiradone had no effect on fibroblast growth factor (FGF)-2 or epidermal growth factor (EGF)
activity. [160]. Recently, a study using a transgenic mouse model of melanoma exhibited that
the anticancer effects of popular kampo medicine were mediated by an improved antigen-
specific antitumor cytotoxic T-lymphocyte response [151, 161].
8. Conclusions
Despite the scientific interests and advances in the past few decades of natural products
research, to date efforts to discover new bioactive agents from the flora for use as chemical
leads in the development of new drugs have not experienced the expected progress. There is
a need to strategize research approach which should be based on the integration of human and
technology resources available and the establishment of smart partnerships between academic
and research institutions, industries and multinational drug coorporations. We need to learn
from the past successful research experiences to increase the chances of discovering new drugs
from the tropical rainforests. The right research strategy has to be used but it will take more
than a few decades for countries of the tropical rainforests to establish their research and drug
design capacity and be a serious competitor in the pharmaceutical markets. We have to be up-
to-date with the newly emerging technologies which are already playing highly significant
roles in natural product research such as the advances in high-throughput screening method‐
ologies, the development of molecular biology and biotechnology and the use of virtual
technology in rational drug design. The role of combinatorial chemistry in drug discovery and
the future impact of genomics, proteomics and metabolomics in medicinal plant research
should also be given due consideration. The potential of rainforests natural products to become
new drugs is still on the horizon. The recent adoption of the Nagoya Protocol of the Convention
on Biological Diversity on 29 October 2010 in Nagoya, Aichi Province, Japan, on access to
genetic resources and the fair and equitable sharing of benefits arising from their utilization
should encourage more pharmaceutical firms to venture into natural research to discover new
drug leads [162]. The protocol provides a transparent legal framework for the effective
implementation of a fair and equitable sharing of benefits between participating parties arising
out of the utilization of genetic resources. However, the number of plants that have been
studied extensively to search for new drugs is very few. A very small fraction, which is less
than 5% of tropical forest plant species have been scanned for their chemical composition and
medicinal values [163]. The figures are not unusual as systematic drug discovery programmes
from plants are largely carried out by multinational drug corporations or research groups of
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the industrialized countries which possess the technology resources and well-equipped
research facilities but have little access to the tropical plant genetic resources. In tropical
countries rather most tropical countries there is little and minor concern for systematic research
effort, to screen plants for new drugs, and the reason is the capacity to investigate these
resources to their full potential and other aspects is very limited in these countries. Neverthless
instead of this, several commercial activities such as clearing of forests for agricultural
purposes and timber extraction predominate and are rapidly destructing the plant genetic
resources.
Chemical prospecting in the tropical rainforests for potential drugs is still progressing. The
prospective for drug discovery from plants and other natural sources is huge, but little time
remains to discover this speedily diminishing resource. Given the quick devastation of tropical
habitats, particularly the rainforests, and the degradation of marine ecologies, this deficiency
of information is alarming. The wealth of potential drugs has two potential sources: either from
the rainforest or from the laboratory. We need to stress here that the future of drug discovery
lies in neither of these options alone, rather it embodies both the rainforest and the laboratory.
Combinatorial laboratory technique, which is a relatively newly emerging technique, is
growing in proficiency with support from pharmaceutical companies. And as new combina‐
torial libraries emerge, the ability and chance to quickly synthesize and derivative a biologi‐
cally active compound increases. But even with this technology, there cannot be a substitution
for the biodiversity that can be found within the boundaries of the rainforests.
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